Blood Lead Above the Action Level at a Battery Plant
A 38-year-old man has worked four years in the grid-casting area of a lead-acid battery plant. Airborne lead has averaged 62 µg/m³ over the last six months (PEL 50 µg/m³). He has no symptoms. His first blood lead level (BLL) in the company surveillance program is 42 µg/dL; a repeat two weeks later, drawn as required after any BLL of 40 or above, is 47 µg/dL. Hemoglobin is 13.6 g/dL and zinc protoporphyrin is 55 µg/dL. The company's written lead program sets medical removal at a BLL of 60 µg/dL. The plant manager asks whether the employee must be removed now, and the employee's family physician has suggested oral chelation 'to be safe.' The employee wants to keep working and asks whether these levels are dangerous.
1. Under the current OSHA lead standard, does this employee meet criteria for medical removal? Walk through the thresholds and state what must happen now.
Read the worked answer
Under 29 CFR 1910.1025(k), medical removal is triggered by a single BLL of 60 µg/dL or higher, or an average of 50 µg/dL or higher across the three most recent tests (or all tests in the prior six months if fewer than three exist). This man's two results, 42 and 47, average 44.5, so he does not yet meet either removal trigger. What is required now: because he exceeds 40 µg/dL, the employer must offer a medical examination, and it must notify him in writing of the BLL results within five working days of receiving them. Because airborne lead exceeds the PEL, engineering and work-practice controls plus interim respiratory protection are mandatory, along with periodic air monitoring and a written compliance plan. The company's 60 µg/dL 'trigger' is incomplete - the 50 µg/dL three-month average is an independent trigger. If he is removed, he is entitled to medical removal protection benefits for up to 18 months, so removal is not a penalty. Continue BLL monitoring at least every two months at this level.
2. Is chelation indicated? Explain the reasoning.
Read the worked answer
Chelation is not indicated. It is reserved for severe poisoning - typically symptomatic patients, encephalopathy, or BLLs around 70 µg/dL and above - and should be directed by a specialist with inpatient monitoring. In an asymptomatic worker with a BLL under 45 µg/dL, chelation has no demonstrated benefit and carries real risks: hepatotoxicity, nephrotoxicity, hypocalcemia, and rebound as bone stores redistribute. It can also mask the exposure signal that should drive workplace controls. The correct first steps are exposure control and removal if thresholds are met, with continued biological monitoring. The family physician's suggestion should be addressed directly, explained to the patient, and documented in the record.
3. What immediate workplace controls and program changes should be implemented?
Read the worked answer
Source control first: enclosure or local exhaust ventilation at casting and smelting operations, with air monitoring to verify levels below the PEL. Until controls are effective, provide at minimum a half-face respirator with P100 filters, including fit testing and medical clearance. Add hygiene facilities - showers, change rooms, separate work clothing, no eating or smoking in the area - and HEPA vacuuming rather than dry sweeping. Provide training and signage, repeat airborne sampling, and re-evaluate the written lead program, including the removal triggers, so they match the standard. Offer the medical examination now, track BLLs on the required schedule, and consider temporary reassignment as a voluntary protective measure even below the removal threshold.